We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis
Effects of GLP-1 treatments on weight and metabolism in people with inflammatory bowel disease
AI simplified
Abstract
The pooled weight change following treatment was -5.71 Kg.
- A total of eight retrospective cohort studies involving 1236 patients were reviewed.
- Weight loss was significant in the semaglutide subgroup, with a mean change of -5.59 Kg.
- Significant reductions in body mass index () were observed, with a mean change of -2.18 Kg/m.
- The certainty of evidence for weight change was rated as 'Low,' and 'Very Low' for other outcomes.
- Potential bias in the included studies and small sample sizes limit the robustness of the findings.
- Further prospective studies are needed to confirm the efficacy of GLP-1 receptor agonists in the IBD population.
AI simplified
Key numbers
-5.71 Kg
Mean Weight Loss
Pooled mean change from baseline to follow-up.
-2.18 Kg/m²
Mean Reduction
Pooled mean change from baseline to follow-up across studies.
-5.59 Kg
Semaglutide Weight Change
Mean raw change in weight for the semaglutide subgroup.